The prevalence of heart failure in patients with diabetes is four times higher than in the general population. Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe. Does it improve outcomes in patients with heart failure or CKD?
Guest Authors: Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP
Music by Good Talk
Guiding Antiplatelet Therapy: Is a Personalized Approach Worth It?
Psilocybin for Depression: Is it Worth the Trip?
Up the Creek Without a Paddle? Look to Your Pharmacist to Bridge-It
SGLT2i plus MRAs for Heart Failure: A Sweet or Sour Combination?
Is As-Needed Nasal Corticosteroid Use Needed for Allergic Rhinitis Management?
STEP-ping Up the Game for Weight Management
Tiny (n-of-1) Trials to Overcome Statin-Associated Muscle Pain
Top Ten Things Every Clinician Should Know About Infographics
Mind Over Migraine: Can Mindfulness Improve Outcomes?
Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?
Increasing the Patient-Clinician Connection: the “Presence 5 Practices”
FAST Take: Update on Febuxostat Cardiovascular Safety
Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?
Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?
There’s an App for That! Can Smartphone Apps Assist with Smoking Cessation?
DECLARE-ing Another Victory for Dapagliflozin
Closing the Loop for Children with Type 1 Diabetes
Is it Time to Add Colchicine to the CVD Cocktail?
Canagliflozin Comeback? New Data on the Risk of Amputation
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive